Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial by Long, Georgina V, Prof, Atkinson, Victoria, MBBS, Cebon, Jonathan S, Prof, Jameson, Michael B, MBChB, Fitzharris, Bernie M, MD, McNeil, Catriona M, PhD, Hill, Andrew G, MBBS, Ribas, Antoni, Prof, Atkins, Michael B, Prof, Thompson, John A, Prof, Hwu, Wen-Jen, Prof, Hodi, F Stephen, Prof, Menzies, Alexander M, MBBS, Guminski, Alexander D, MBBS, Kefford, Richard, Prof, Kong, Benjamin Y, MBBS, Tamjid, Babak, MD, Srivastava, Archana, MBBS, Lomax, Anna J, MBBS, Islam, Mohammed, MBBS, Shu, Xinxin, PhD, Ebbinghaus, Scot, MD, Ibrahim, Nageatte, MD, Carlino, Matteo S, MBBS

Get full text